About Camena Bioscience

Camena Bioscience develops gSynth®, an enzyme-based DNA synthesis platform that produces synthetic genes of any sequence, length and complexity at high throughput. The technology addresses critical bottlenecks in traditional methods, enabling researchers to manufacture genes that have been historically difficult to produce, from kilobase-length sequences to highly repetitive constructs. The platform serves pharmaceutical companies, biotechnology firms and researchers developing mRNA vaccines, cell and gene therapies, and CRISPR applications. By eliminating harmful solvents and reducing synthesis timelines, Camena supports healthcare decarbonisation whilst accelerating drug discovery and enabling next generation therapeutics.